Psychedelic Research and Access in
South Africa
Blossom currently tracks 6 psychedelic clinical trials connected to South Africa. The country page also links to 1 stakeholder, giving the page ecosystem context beyond registered studies.
Data updated
Key Insights
A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inSouth Africa.
- 1
Blossom tracks 6 psychedelic clinical trials connected to South Africa, with none currently marked active.
- 2
Visible trial compounds include Esketamine.
- 3
Visible trial topics include Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).
- 4
The country page links to 1 stakeholder in Blossom's ecosystem data.
- 5
The country access guide currently classifies access as "Medical Only (Private)"; details vary by compound and care setting.
Research and Access Snapshot
Blossom currently tracks 6 psychedelic clinical trials connected to South Africa.
- Active trials
- 0
- Total trials
- 6
- Stakeholders
- 3
- Events
- 0
None marked active
Linked to this country
Linked organisations
No linked events
Top Compounds
- Esketamine(6)
Top Study Topics
- Treatment-Resistant Depression (TRD)(4)
- Major Depressive Disorder (MDD)(2)
Medical Access
South Africa maintains a restrictive, medically-regulated approach to classic and novel psychedelics. Ketamine is an established medical anesthetic and is used off-label for depression in specialist settings; esketamine (Spravato) has been reported as available through registered channels. Most classical serotonergic psychedelics (psilocybin, MDMA, DMT, 5-MeO-DMT, mescaline, 2C-X) and sacramental preparations (ayahuasca) remain controlled with no routine reimbursed medical availability outside authorised research or tightly regulated exemptions.
Research Landscape
What the 6 registered trials connected to South Africa look like when you line them up. Counts come from Blossom’s trial records as of July 2026.
What's live right now, and what stopped?
SourcedRegistry status of all 6 South Africa trials Blossom tracks. Orange marks trials recruiting or opening.
Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.
Regulatory Status
The linked medical access and reimbursement guide summarises South Africa as "Medical Only (Private)". South Africa maintains a restrictive, medically-regulated approach to classic and novel psychedelics. Ketamine is an established medical anesthetic and is used off-label for depression in specialist settings; esketamine (Spravato) has been reported as available through registered channels.
Country Details
- Region
- Africa
- Last updated
- 15 Jul 2026
Country Report
Medical Only (Private)Medical Access
South Africa maintains a restrictive, medically-regulated approach to classic and novel psychedelics. Ketamine is an established medical anesthetic and is used off-label for depression in specialist settings; esketamine (Spravato) has been reported as available through registered channels. Most...
Open access guide →Pro Scorecard
Country Scorecard
Compare evidence, access, payment, delivery, local ecosystem, and review confidence for South Africa.
Open scorecard →Psychedelic Stakeholders in South Africa
Organisations, sponsors, clinics, and research groups connected to psychedelic science in South Africa.
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in South Africa.